CEDULOR

EU Funding Notes

As of 19 November 2026
Llull Lab

Programme

Horizon Europe: Health

Open and forthcoming calls listed on the EU Funding and Tenders Portal, sorted by the next deadline. 16 calls listed, 13 open for submission.

HORIZON Research and Innovation Actions

Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

Open Closes on 90 days left

Indicative budget: EUR 8.0 to 10.0 million per grant, about 4 grants expected (2027).

Funds research into personalised approaches to reduce adverse drug reactions caused by administration of multiple medications, integrating genetic and biomarker information into clinical decision making to improve patient safety, health outcomes, and cost efficiency in healthcare systems.

HORIZON Research and Innovation Actions

Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential

Open Closes on 90 days left

Indicative budget: EUR 9.0 to 11.0 million per grant, about 5 grants expected (2027).

Funds research and innovation to develop novel small molecule antiviral therapeutics targeting pathogens with epidemic potential, aiming to expand therapeutic options and improve preparedness for emerging or re-emerging viral outbreaks accelerated by climate change.

HORIZON Research and Innovation Actions

Development of monoclonal antibodies to prevent and treat infections from Flaviviruses

Open Closes on 90 days left

Indicative budget: EUR 9.0 to 10.0 million per grant, about 4 grants expected (2027).

HORIZON Research and Innovation Actions

Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses

Open Closes on 90 days left

Indicative budget: EUR 9.0 to 10.0 million per grant, about 4 grants expected (2027).

Funds the development of monoclonal antibodies targeting Filo-, Nairo-, Phenui-, Picorna- and Togaviruses, aiming to deliver candidate therapies for prevention and treatment of emerging or re-emerging viral infections with epidemic or pandemic potential.

HORIZON Research and Innovation Actions

Development of innovative antimicrobials against pathogens resistant to antimicrobials

Open Closes on 90 days left

Indicative budget: EUR 8.0 to 10.0 million per grant, about 5 grants expected (2027).

Funds development of innovative antimicrobial products against drug-resistant bacteria and fungi, aiming to expand therapeutic options and strengthen the clinical response to the growing threat of antimicrobial resistance.

HORIZON Research and Innovation Actions

Prevention and management of chronic non-communicable diseases in children and young people (GACD)

Open Closes on 90 days left

Indicative budget: EUR 3.0 to 4.0 million per grant, about 3 grants expected (2027).

Funds research on prevention and management of chronic non-communicable diseases in children and young people, particularly in low- and middle-income countries and disadvantaged populations, aiming to improve early prevention, diagnosis, and quality of life. Aligned with the Global Alliance for Chronic Diseases.

HORIZON Research and Innovation Actions

Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change

Open Closes on 90 days left

Indicative budget: EUR 10.0 to 11.0 million per grant, about 4 grants expected (2027).

Funds research integrating climate-related exposures into the human exposome framework, aiming to improve understanding of how climatic, environmental and socio-behavioural factors interact to affect health outcomes and to support climate-resilient public health strategies.

HORIZON Research and Innovation Actions

Development of cell-free protein synthesis platforms for discovery and/or production of biologicals

Open Closes on 90 days left

Indicative budget: EUR 6.0 to 8.0 million per grant, about 4 grants expected (2027).

Funds development of cell-free protein synthesis platforms for discovering and producing peptide- or protein-based biologicals, aiming to streamline biopharmaceutical production processes and improve patient access to affordable medicines.

HORIZON Research and Innovation Actions

Addressing disabilities through the life course to support independent living and inclusion

Open Closes on 90 days left

Indicative budget: EUR 6.0 to 8.0 million per grant, about 5 grants expected (2027).

Funds research on addressing disabilities across the life course, aiming to develop innovative solutions that remove barriers to independent living, community inclusion, and equal participation in society for persons with long-term disabilities.

HORIZON Research and Innovation Actions

Innovative healthcare interventions for non-communicable diseases

Open Stage 1 closes on Stage 2 closes on 90 days left

Indicative budget: EUR 7.0 to 8.0 million per grant, about 8 grants expected (2027).

Funds research and innovation to develop and validate innovative healthcare interventions for non-communicable diseases, specifically cardiovascular diseases, diabetes, chronic respiratory diseases, or chronic kidney diseases, through late-stage clinical trials and FAIR data sharing.

HORIZON Research and Innovation Actions

Clinical trials for advancing innovative interventions for neurodegenerative diseases

Open Stage 1 closes on Stage 2 closes on 90 days left

Indicative budget: around EUR 10.0 million per grant, about 4 grants expected (2027).

HORIZON Innovation Actions

Portable and versatile Point-of-care diagnostics

Open Stage 1 closes on Stage 2 closes on 90 days left

Indicative budget: EUR 5.0 to 7.0 million per grant, about 6 grants expected (2027).

HORIZON Research and Innovation Actions

Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases

Open Stage 1 closes on Stage 2 closes on 90 days left

Indicative budget: EUR 6.0 to 8.0 million per grant, about 6 grants expected (2027).

Funds the development of predictive biomarkers for disease progression and treatment response in chronic non-communicable diseases using AI methodologies, aiming to advance personalised medicine and improve clinical outcomes through validated, trustworthy tools.

HORIZON Research and Innovation Actions

Advancing bio-printing of living cells for regenerative medicine

Opens on Closes on 301 days left

Indicative budget: EUR 7.0 to 10.0 million per grant, about 4 grants expected (2027).

Funds research and innovation to advance bio-printing of living cells for regenerative medicine, aiming to deliver functional tissue-specific 3D bio-printing units for transplantation applications and enable personalised treatments for conditions of unmet medical need.

HORIZON Research and Innovation Actions

Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis

Opens on Closes on 301 days left

Indicative budget: EUR 10.0 to 12.0 million per grant, about 4 grants expected (2027).

Funds research developing Virtual Human Twin models as multi-scale, multi-organ digital representations of individual patients to support integrated clinical decision-making in prevention and diagnosis, improving personalised care across diverse patient populations.

HORIZON Coordination and Support Actions

Towards the next generation of frontier Artificial Intelligence models for healthcare

Opens on Closes on 301 days left

Indicative budget: around EUR 2.9 million per grant, one grant expected (2027).

Funds coordination and support activities to build a collaborative roadmap for developing next-generation frontier AI models for healthcare, improving understanding of how to use AI Factories, foundation models, and highly heterogeneous multimodal health data for inclusive and personalised medicine.

Titles, identifiers, types of action, dates and indicative budgets come from the EU Funding and Tenders Portal; statuses are as of the date at the top of the page. Deadlines are usually at 17:00 Brussels time: confirm each call's status, conditions and exact deadline time on its official topic page before you rely on it. Cedulor is independent and not affiliated with the European Union or its research bodies.